BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17986279)

  • 41. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
    Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
    Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma.
    Balenović A; Vlasić M; Sonicki Z; Bodor D; Kusić Z
    Coll Antropol; 2006 Dec; 30(4):743-8. PubMed ID: 17243543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of radioactive iodine therapy in young patients with papillary thyroid cancer.
    Kuo SF; Chao TC; Chang HY; Hsueh C; Chang YC; Yang CH; Lin JD
    Clin Nucl Med; 2009 Jan; 34(1):4-6. PubMed ID: 19092372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatic metastasis of differentiated thyroid carcinoma.
    Kraft O
    Nucl Med Rev Cent East Eur; 2005; 8(1):44-6. PubMed ID: 15977146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radioiodine therapy for thyroid volume reduction of large goitres.
    Bachmann J; Kobe C; Bor S; Rahlff I; Dietlein M; Schicha H; Schmidt M
    Nucl Med Commun; 2009 Jun; 30(6):466-71. PubMed ID: 19381116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II multicenter clinical trial of systemic bexarotene in psoriasis.
    Smit JV; Franssen ME; de Jong EM; Lambert J; Roseeuw DI; De Weert J; Yocum RC; Stevens VJ; van De Kerkhof PC
    J Am Acad Dermatol; 2004 Aug; 51(2):249-56. PubMed ID: 15280844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hurthle cell neoplasm of the thyroid gland.
    Ahmed M; Bin Yousef H; Greer W; Faraz H; Al Sobhi S; Al Zahrani A; Raef H; Al Ghamdi A; Al Kadhi Y; Al Dayel F
    ANZ J Surg; 2008 Mar; 78(3):139-43. PubMed ID: 18269475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapy of large multinodular goitre using repeated doses of radioiodine.
    Baczyk M; Pisarek M; Czepczyński R; Ziemnicka K; Gryczyńska M; Pietz L; Sowiński J
    Nucl Med Commun; 2009 Mar; 30(3):226-31. PubMed ID: 19262285
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating thyroglobulin mRNA does not predict early and midterm recurrences in patients undergoing thyroidectomy for cancer.
    Lombardi CP; Bossola M; Princi P; Boscherini M; La Torre G; Raffaelli M; Traini E; Salvatori M; Pontecorvi A; Bellantone R
    Am J Surg; 2008 Sep; 196(3):326-32. PubMed ID: 18614150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients.
    Schlumberger M; Lacroix L; Russo D; Filetti S; Bidart JM
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):260-9. PubMed ID: 17315034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin.
    Smit JV; de Jong EM; van Hooijdonk CA; Otero ME; Boezeman JB; van de Kerkhof PC
    J Am Acad Dermatol; 2004 Aug; 51(2):257-64. PubMed ID: 15280845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment.
    Fallahi B; Adabi K; Majidi M; Fard-Esfahani A; Heshmat R; Larijani B; Haghpanah V
    Clin Nucl Med; 2011 Apr; 36(4):277-82. PubMed ID: 21368600
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0.
    Lin JD; Lin KJ; Chao TC; Hseuh C; Tsang NM
    Radiother Oncol; 2008 Oct; 89(1):97-104. PubMed ID: 18534700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.
    Joseph LJ; Bhartiya US; Raut YS; Kand P; Hawaldar RW; Nair N
    Mutat Res; 2009 Apr; 675(1-2):35-40. PubMed ID: 19386245
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma.
    Sawka AM; Orlov S; Gelberg J; Stork B; Dowar M; Shaytzag M; Tabatabaie V; Freeman JL; Walfish PG
    Head Neck; 2008 Jun; 30(6):693-700. PubMed ID: 18098308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel treatment of chronic severe hand dermatitis with bexarotene gel.
    Hanifin JM; Stevens V; Sheth P; Breneman D
    Br J Dermatol; 2004 Mar; 150(3):545-53. PubMed ID: 15030340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical outcomes of adjuvant external-beam radiotherapy for differentiated thyroid cancer - results after 874 patient-years of follow-up in the MSDS-trial.
    Biermann M; Pixberg M; Riemann B; Schuck A; Heinecke A; Schmid KW; Willich N; Dralle H; Schober O;
    Nuklearmedizin; 2009; 48(3):89-98; quiz N15. PubMed ID: 19322503
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study.
    Stokkel MP; Verkooijen RB; Bouwsma H; Smit JW
    Nucl Med Commun; 2004 Jul; 25(7):683-90. PubMed ID: 15208495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.